Navigation Links
Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
Date:7/13/2009

ALLEGAN, Mich., July 13 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex lozenge USP, 2 mg and 4 mg in cherry and cinnamon flavors.

The new products will be marketed under store brand labels and are comparable to GlaxoSmithKline's Commit(R) lozenge, which is an aid to smoking cessation. Perrigo's Chairman and CEO Joseph C. Papa stated, "These two approvals expand our exclusive position in the store brand nicotine lozenge category. The expanded range of smoking cessation products also includes coated mint and Fruit Chill(TM) flavored gum, uncoated gum and lozenges." The smoking cessation category is selling at an annual rate estimated at approximately $1 billion at all retail outlets. We expect to begin shipments in the near future.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
2. Perrigo Reports Record Third Quarter
3. Perrigo Company Announces Quarterly Dividend
4. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
5. Perrigo Begins Shipments of Ibuprofen PM
6. Perrigo Reports Record Second Quarter Sales
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
9. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
10. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
11. Perrigo Announces FDA Final Approval for Ibuprofen PM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and well-known ... to offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon ... Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud to ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. ... of directors: Christopher Gabrieli ... serve as chairman of the board of Akcea Therapeutics. ... of Forest Laboratories. Sandford D. Smith ... "We are excited to announce this expansion to ...
(Date:3/28/2017)... , March 28, 2017 ... expected to reach a value of USD 4.5 billion ... View Research, Inc. Proper closure of injured tissues post ... and function. Postoperative leakages occur in 3% to 15% ... They are responsible for one third of postoperative deaths ...
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
Breaking Medicine Technology: